CorMedix commercializes DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. The product addresses a hospital and dialysis-clinic infection-control niche rather than a broad primary-care drug franchise. Its commercial focus is specialty distribution into U.S. dialysis and acute-care settings.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 39.7 | — | 19.8 | — |
| Q3 2025 | 104.3 | — | 108.6 | — |
| Q4 2025 | 128.6 | — | 13 | -2.4% |
| Q1 2026 | 127.4 | — | 38.4 | 96.2% |
| Q2 2026 | 99.3 | 149.9% | 26 | 31.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Climb Bio Inc (CLYM), Phathom Pharmaceuticals, Inc. (PHAT), Civista Bancshares, Inc. (CIVB), HIVE Digital Technologies Ltd. (HIVE), Bank7 Corp. (BSVN), Hallador Energy Company (HNRG)